Amgen’s Q1 Overshadowed By Tax Dispute That May Cost $7.1bn To Resolve
IRS Identifies $5.1bn Shortfall, Proposes $2bn Penalty
Executive Summary
First quarter revenue of $6.2bn and product sales of $5.7bn were up 6% and 2%, respectively, year over year. However, a looming – and potentially growing – tax liability is a multibillion-dollar overhang.
You may also be interested in...
Amgen To Enhance Rare Disease Franchise With $27.8bn Horizon Takeover
The US major has announced its biggest acquisition to date in the form of a takeover that should expand its rare disease franchise and stave off concerns about internal products facing biosimilar competition.
Can Can-Fite’s Piclidenoson Put Up A Fight In Psoriasis?
Can-Fite’s A3AR agonist was inferior to Amgen’s Otezla by most efficacy measures, while Bristol Myers Squibb’s competing deucravacitinib is closer to approval and did beat Otezla.
Amgen/Takeda ASCO Data Could Help Guide Vectibix Use In mCRC
The PARADIGM study took place in Japan, but it was described as the first to prospectively evaluate treatment of wild-type RAS mCRC and left-sided primary tumors.